High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: a phase II study.
Sixteen patients with metastatic nonseminomatous testicular cancer refractory to cisplatinum combination chemotherapy, were treated with epirubicin 100-120 mg/m2 q d 22. One partial remission lasting 6 months was achieved. Two additional patients had stabilisation of disease for 3 and 4 months. Median time to progression was 43 days. Myelosuppression was dose-limiting, with a WBC nadir of 1900/microliters. 4/30 cycles (13%) were associated with granulocytopenic fever. One patient developed a decline in cardiac ejection fraction without clinical signs of congestive heart failure. Epirubicin in this dosage and schedule has no major therapeutic activity in heavily pretreated non-seminomatous testicular cancer.
Harstrick
A
A
Department of Hematology/Oncology, University of Hannover Medical School, FRG.
Schmoll
H J
HJ
Wilke
H
H
Schöber
C
C
Stahl
M
M
Wömpner
C K
CK
Bokemeyer
C
C
Dölken
G
G
Burk
K
K
Poliwoda
H
H
D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012074:Remission Induction; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000401:mortality
D015251:Epirubicin